脑脊液α-突触核蛋白种子扩增检测结果与可能及很可能路易体痴呆临床特征的关联
在191例临床诊断的路易体痴呆(DLB)患者、50例年龄性别匹配的临床对照和49例年轻分析对照中,72%的DLB患者脑脊液α-突触核蛋白种子扩增检测(αSyn-SAA)阳性,对照组为4%。在DLB患者中,αSyn-SAA阳性与更低的蒙特利尔认知评估评分、更差的帕金森综合征、更常见的快速眼动睡眠行为障碍(RBD)和更差的嗅觉相关,嗅觉减退是αSyn-SAA阳性的最强临床预测因素。
要点
- 72%(137/191)临床诊断DLB患者脑脊液αSyn-SAA阳性,对照组为4%。
- DLB患者中αSyn-SAA阳性者认知、帕金森综合征、RBD和嗅觉均更差。
- 嗅觉测试百分位预测αSyn-SAA阳性的曲线下面积为0.87(95%CI 0.81-0.94)。
核心结论
- 相当比例的临床诊断DLB患者αSyn-SAA结果为阴性。
- 嗅觉减退是αSyn-SAA阳性的最强临床预测因素。
- 嗅觉减退和αSyn-SAA可能有助于改善潜在DLB个体的诊断评估。
研究设计与样本
- 横断面和纵向脑脊液样本来自DLB联盟多中心观察性队列研究及帕金森病生物标志物计划中的类似研究,由美国学术医学中心提供。
- 纳入临床诊断的DLB患者191例(平均年龄69.9±6.8岁,女性15%)、年龄和性别匹配的临床对照50例及年轻分析对照49例。
- 使用逻辑回归评估DLB核心特征和嗅觉与αSyn-SAA阳性的关联。
主要发现
- DLB患者中72%(137/191)αSyn-SAA阳性,对照组为4%。
- αSyn-SAA阳性的DLB患者蒙特利尔认知评估评分较低(18.8±5.7 vs 21.2±5.2,p=0.01)。
- αSyn-SAA阳性的DLB患者运动障碍学会统一帕金森病评定量表第三部分评分较差(33.8±15.1 vs 25.6±16.4,p=0.001)。
- αSyn-SAA阳性的DLB患者更常报告RBD(114/133 [86%] vs 33/53 [62%],p<0.0001)。
- αSyn-SAA阳性的DLB患者嗅觉减退更严重,UPSIT百分位低于第15百分位者比例更高(94/105 [90%] vs 14/44 [32%],p<0.0001)。
关键数值与推荐
- UPSIT百分位预测αSyn-SAA阳性的曲线下面积为0.87(95%CI 0.81-0.94)。
- UPSIT评分在年龄和性别常模第15百分位或以下的参与者αSyn-SAA阳性比值比为18.3(95%CI 7.52-44.6)。
- 82例有纵向脑脊液样本的参与者中,81例(99%)初始和随访标本的αSyn-SAA结果相同。
- 本研究提供III级证据表明脑脊液αSyn-SAA可区分临床诊断的DLB患者与正常对照。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The clinical diagnosis of dementia with Lewy bodies (DLB) depends on identifying significant cognitive decline accompanied by core features of parkinsonism, visual hallucinations, cognitive fluctuations, and REM sleep behavior disorder (RBD). Hyposmia is one of the several supportive features. α-Synuclein seeding amplification assays (αSyn-SAAs) may enhance diagnostic accuracy by detecting pathologic αSyn seeds in CSF. In this study, we examine how different clinical features associate with CSF αSyn-SAA positivity in a large group of clinically diagnosed participants with DLB. METHODS: Cross-sectional and longitudinal CSF samples from the multicentered observational cohort study of the DLB Consortium and similar studies within the Parkinson's Disease Biomarker Program, contributed by academic medical centers in the United States, underwent αSyn-SAA testing. Participants included those clinically diagnosed with DLB and 2 control cohorts. Associations between core DLB features and olfaction with αSyn-SAA positivity were evaluated using logistic regression. RESULTS: CSF samples from 191 participants diagnosed with DLB (mean age 69.9 ± 6.8, 15% female), 50 age-matched and sex-matched clinical control participants, and 49 younger analytical control participants were analyzed. Seventy-two percent (137/191) of participants with DLB had positive αSyn-SAAs vs 4% of the control groups. Among participants with DLB, those who were αSyn-SAA-positive had lower Montreal Cognitive Assessment scores (18.8 ± 5.7 vs 21.2 ± 5.2, p = 0.01), had worse parkinsonism on the Movement Disorders Society Unified Parkinson's Disease Rating Scale part III (33.8 ± 15.1 vs 25.6 ± 16.4, p = 0.001), were more likely to report RBD (114/133 [86%] vs 33/53 [62%], p < 0.0001), and had worse hyposmia on the University of Pennsylvania Smell Identification Test (UPSIT) (94/105 [90%] below 15th percentile vs 14/44 [32%], p < 0.0001). UPSIT percentile had the highest area under the curve (0.87, 95% CI 0.81-0.94) in predicting αSyn-SAA positivity and participants scoring at or below the 15th percentile of age and sex normative values had 18.3 times higher odds (95% CI 7.52-44.6) of having a positive αSyn-SAA test. Among 82 participants with longitudinal CSF samples, 81 (99%) had the same αSyn-SAA result for initial and follow-up specimens. DISCUSSION: A substantial proportion of clinically diagnosed participants with DLB had negative αSyn-SAA results. Hyposmia was the strongest clinical predictor of αSyn-SAA positivity. Hyposmia and αSyn-SAA may have utility in improving the diagnostic assessment of individuals with potential DLB. CLASSIFICATION OF EVIDENCE: This study provided Class III evidence that CSF αSyn-SAA distinguishes patients with clinically diagnosed DLB from normal controls.
引用
- Coughlin DG, MacLeod KR, Middleton JS, et al. Association of CSF α-Synuclein Seeding Amplification Assay Results With Clinical Features of Possible and Probable Dementia With Lewy Bodies. Neurology. 2024. PMID: 39013126. doi:10.1212/WNL.0000000000209656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。